BioSpace News Archive

Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today announced the publication of fecal incontinence study results for patients treated with the Axonics r-SNM System.

The Alzheimer Society of Canada is disappointed to hear that, after reviewing data from Phase 3 clinical trials, a U.S. Food and Drug Administration advisory panel did not find conclusive evidence that a potential new treatment for Alzheimer’s was effective at reducing cognitive decline.

Pfizer has announced that early results in its COVID-19 vaccine trial show an astonishing 90 percent efficacy , notes Physicians for Civil Defense. “In 10 years only three other vaccines with efficacy greater than 50 percent have been developed.” Of about 40,000 volunteers who received two doses of the experimental vaccine, 9

R-Zero, a biosafety company dedicated to developing the most effective hospital-grade technologies to reduce the spread of infectious disease, today announced $15M in new capital and remarkable business momentum, just three months after first introducing its germicidal UV device.

Amedisys, Inc., one of America’s leading home health, hospice and personal care companies, announced that Paul B. Kusserow, President and Chief Executive Officer will present at the Stephens Annual Investment Conference 2020 on Thursday, November 19, 2020.

Huntington Hospital announced that Ranjit S. Hundal, MD, MBA, FACPE, is joining the hospital’s executive management team as Senior Vice President, Chief Clinical Officer.

Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the third quarter and nine months ended September 30, 2020. Third Quarter 2020 and Recent Corporate Highlights Announced updated top-line results from Phase III DESTINY PWS (C601) study evaluating once-d

Editas Medicine, Inc., a leading genome editing company, announced the grant of inducement awards to the Company’s newly appointed Executive Vice President and Chief Medical Officer, Lisa Michaels, M.D.

Analysis of results from EMERGE ™ Phase 3 efficacy trial of STS101 ongoing; expect to communicate next steps by early 2021 C ash , cash equivalents and marketable securities of $ 82.1 million as of September 30 , 2020; based on current operating plans, expected to provide runway through end of 2021

Silk Road Medical, Inc., a company focused on reducing the risk of stroke and its devastating impact, reported financial results for the three months ended September 30, 2020.